Introduction:
Can a CDMO manufacture both peptides and biologics? Yes, a Contract Development and Manufacturing Organization (CDMO) can support both, but its capabilities depend on its facilities, technologies, quality systems and experience with the specific molecule. Demand for integrated Peptide and Biologics CDMO Services is growing as sponsors try to reduce vendor hand-offs and shorten timelines.
Peptides and biologics share some analytical and quality requirements, yet their manufacturing processes differ considerably. As pipelines expand to include peptide therapeutics, monoclonal antibodies, recombinant proteins and hybrid molecules, companies must evaluate more than capacity. They also need to weigh analytical characterization, impurity control, process development, stability testing and regulatory documentation.
It is also important to distinguish between a CDMO that manufactures drug substance in-house and an analytical laboratory that provides specialized testing and characterization. ResolveMass Laboratories Inc. is a Canadian analytical CRO/CDMO with experience in biosimilar characterization, mass spectrometry, PLGA-based drug delivery and nitrosamine testing. This guide reflects how we approach these questions.
Summary:
- Short answer: Yes, a CDMO can support both peptide and biologic development, provided it has the right facilities, technologies, quality systems and molecule-specific experience.
- Different science: Peptides are typically made by chemical synthesis (SPPS or liquid-phase). Biologics, such as monoclonal antibodies and recombinant proteins, are produced in biological expression systems, then purified.
- Different impurities: Peptide risks include deletion sequences, oxidation and epimerization. Biologic risks include aggregation, glycosylation variability and host-cell proteins.
- Integrated value: Integrated Peptide and Biologics CDMO Services can coordinate analytical development, impurity profiling, stability studies and technology transfer.
- Verify in-house vs. partnered work: Analytical characterization does not by itself prove in-house manufacturing. Always confirm manufacturing capacity, cGMP status and who is responsible for each stage.
- Analytics decide quality: LC-MS, LC-HRMS and orthogonal methods are what prove identity, purity and consistency.
1: What Is a CDMO, and What Services Does It Provide?
A CDMO is a specialized organization that supports drug development, process optimization, manufacturing, analytical testing and quality activities. Depending on its capabilities, it may manage the whole development lifecycle or only selected stages. If you are new to the model, our overview of peptide CDMO services explains the basics.
Typical CDMO services include:
- Process development and optimization
- Drug substance and drug product manufacturing
- Analytical method development and validation
- Impurity identification and characterization
- Stability testing and degradation studies
- Formulation development
- Scale-up and technology transfer
- Quality control and regulatory documentation support
Not every CDMO offers all of these. Some specialize in small molecules, while others focus on peptides, biologics, oligonucleotides, sterile injectables or analytical characterization. A peptide-focused CDMO may specialize in chemical synthesis and purification, whereas a biologics-focused CDMO may run mammalian cell culture, microbial fermentation and protein purification platforms. An organization offering both needs genuine expertise and infrastructure for each. For a closer look at the first category, see specialized peptide CDMO services.
Can a CDMO Manufacture Both Peptides and Biologics?
Yes. A CDMO can manufacture both if it has validated or appropriately qualified processes, suitable infrastructure, trained personnel and quality systems designed for the molecules involved. Some organizations cover multiple modalities, while others collaborate with specialist partners. Supporting both categories does not mean the same equipment or process can be used interchangeably.
Peptide Manufacturing Capabilities
Peptides are chains of amino acids joined by peptide bonds. Therapeutic peptides are usually made by chemical synthesis and, for certain molecules, by recombinant or other specialized approaches. Common activities include:
- Solid-phase peptide synthesis (SPPS) and liquid-phase synthesis
- Amino acid coupling, cleavage and deprotection
- Preparative reverse-phase HPLC (RP-HPLC)
- Desalting, counterion exchange and isolation
- Lyophilization and appropriate storage
- Identity, purity and impurity assessment
LC-MS, LC-HRMS and amino acid analysis help establish molecular identity, detect impurities and assess quality. Longer peptides, cyclic peptides, lipidated peptides and peptides with non-natural amino acids add synthesis, purification and characterization challenges. Sponsors comparing providers can start with our guide to the best peptide CDMO selection criteria.
Biologics Manufacturing Capabilities
Biologics are therapeutic products derived from or made using biological systems, including monoclonal antibodies, recombinant proteins and certain enzymes. Manufacturing may involve:
- Cell line development and characterization
- Upstream cell culture or fermentation, protein expression and harvest
- Downstream purification by chromatography and filtration
- Viral clearance and product-specific safety controls
- Formulation development and, where applicable, sterile filtration and aseptic processing
- Structural, physicochemical and biological characterization
Biologics require control of product-related and process-related impurities, including aggregates, fragments, host-cell proteins and residual host-cell DNA. Analytical methods may include peptide mapping, intact mass analysis, size-exclusion chromatography, capillary electrophoresis, glycan analysis and biological activity assays. The exact strategy depends on the biologic’s structure, mechanism of action, process and intended regulatory use.
2: Peptides vs. Biologics: What Are the Main Manufacturing Differences?
Peptides and biologics differ mainly in molecular complexity, production methods, purification requirements and the analytical tools needed to show quality. These differences determine whether a CDMO can effectively support both.
| Parameter | Peptide therapeutics | Biologic therapeutics |
|---|---|---|
| Molecular structure | Relatively short amino acid chains, sometimes with complex modifications | Larger, structurally complex proteins or other biological molecules |
| Typical manufacturing approach | Chemical synthesis or selected biological methods | Cell culture, fermentation, recombinant expression |
| Common production challenges | Incomplete coupling, deletion sequences, oxidation, deamidation | Aggregation, fragmentation, glycosylation variability, misfolding |
| Purification | Often preparative RP-HPLC and related methods | Chromatography, filtration and other downstream operations |
| Identity testing | LC-MS, LC-HRMS, sequence confirmation | Intact mass, peptide mapping, electrophoretic methods |
| Quality assessment | Identity, purity, impurity profile, content, stability | Identity, purity, higher-order structure, biological activity, impurities |
| Infrastructure | Synthesis equipment, solvent handling, purification, isolation | Expression systems, bioprocess equipment, purification platforms, contamination controls |
The term biologics is commonly used in pharmaceutical manufacturing for products such as recombinant proteins and monoclonal antibodies. This matters because the requirements for a chemically synthesized peptide can differ significantly from those for a complex antibody.
3: Why Do Pharmaceutical Companies Need Integrated Peptide and Biologics CDMO Services?
Integrated Peptide and Biologics CDMO Services help coordinate development activities, testing, quality assessments and manufacturing transfers across modalities. Their value depends on whether the provider has the capabilities for each requested activity.
1. Coordinated Analytical Characterization
For peptides, this may include molecular mass confirmation, sequence-related impurity analysis and chromatographic purity. For biologics, it may require intact mass analysis, peptide mapping, glycosylation profiling and aggregation assessment. A coordinated strategy reduces fragmented workflows and helps teams interpret results consistently. Our peptide analytical characterization services page describes the methods in more detail.
2. Impurity Identification and Control
Peptide impurities include:
- Deletion and truncated sequences
- Incomplete coupling products
- Oxidized or deamidated variants
- Epimerized amino acid residues
- Residual synthesis-related impurities
Biologic impurities include:
- Aggregates and fragments
- Charge variants and sequence variants
- Host-cell proteins and residual host-cell DNA
- Residual process reagents
- Product-related modifications and degradation products
LC-MS and LC-HRMS help investigate molecular differences and characterize unknown impurities. Findings must still be interpreted alongside reference materials, validated methods and orthogonal techniques.
3. Improved Development Coordination
Working with a partner that coordinates multiple activities may simplify communication, documentation and technology transfer. Potential advantages include:
- Better alignment between analytical testing and manufacturing requirements
- Earlier identification of product quality risks
- More consistent documentation across stages
- Reduced duplication of analytical work
- Improved planning for scale-up and regulatory submissions
These benefits are not automatic. They depend on the provider’s structure, capabilities, project management and quality systems.
4: What Analytical Services Are Important for Peptides and Biologics?
Analytical characterization demonstrates identity, purity, stability and product quality. Methods should be chosen according to the molecule’s properties, development stage and intended use.
| Analytical requirement | Peptide therapeutics | Biologic therapeutics |
|---|---|---|
| Molecular identity | LC-MS or LC-HRMS, sequence confirmation | Intact mass, peptide mapping, complementary structural methods |
| Purity assessment | RP-HPLC or UPLC | SEC, ion-exchange, reversed-phase methods |
| Impurity characterization | LC-HRMS, MS/MS, targeted impurity analysis | LC-MS/MS, peptide mapping, glycan analysis |
| Structural assessment | Sequence, disulfide bonds where applicable, chemical modifications | Primary structure, disulfide connectivity, higher-order structure, post-translational modifications |
| Aggregation and size variants | Product-dependent methods | SEC, light scattering |
| Stability assessment | Forced degradation, stability-indicating chromatography | Stability studies, aggregation monitoring, functional assessment |
| Biological function | Product-specific potency or functional assays | Product-specific binding, potency or functional assays |
No single method answers every quality question. A matching intact mass does not establish the complete sequence, purity, higher-order structure or activity of a complex biologic. Likewise, a peptide with the expected mass may still contain sequence-related impurities. A risk-based strategy should combine complementary methods.
5: What Should You Evaluate When Selecting a Peptide and Biologics CDMO?
Choose a CDMO whose demonstrated capabilities match your molecule, development stage, manufacturing needs and regulatory goals. A broad service list alone is not evidence of technical suitability.
- Manufacturing infrastructure: For peptides, assess synthesis scale, purification capacity, solvent handling and isolation. For biologics, evaluate expression systems, bioreactor capacity, downstream processing and contamination controls. If you need sterile drug product, confirm aseptic capability.
- Analytical expertise: Confirm they can establish methods for identity, purity, impurity profiling and stability, and ask about experience with complex peptides, antibodies or recombinant proteins.
- Quality management systems: Look for documented procedures, equipment qualification, data integrity controls, deviation management, change control and training records. Confirm cGMP status and actual inspection history where relevant.
- Method validation and regulatory support: Methods should be qualified or validated for their intended purpose and stage. Do not assume a method used on another project is automatically suitable for your submission.
- Scalability and technology transfer: A lab-scale process may need substantial optimization at larger scale. Discuss robustness, yield, purification recovery, batch consistency and analytical comparability. Our guide to peptide technology transfer to a CDMO covers this in depth.
- Transparency on in-house vs. partnered services: Ask which services are performed in-house and which are outsourced. This matters most when a provider advertises both modalities but operates only specialized analytical labs or coordinates manufacturing through partners.
CDMO or CRO: Which Do You Need?
If your immediate need is analytical characterization rather than manufacturing, the distinction between the two models becomes important. Our comparison of peptide CDMO vs. CRO explains when each is the better fit. Sponsors who want a single partner for development and supply can review peptide CDMO services to see what end-to-end support typically includes.
6: Can One CDMO Support Both Modalities from Early Research to Commercial Manufacturing?
Yes, some CDMOs can, but end-to-end coverage must be verified for your specific molecule and stage. Early development focuses on molecular identity, impurity profiling, preliminary stability and process feasibility. Later stages require process characterization, validated methods, manufacturing controls and regulatory documentation.
A typical pathway includes:
- Molecule assessment: Define the target product profile, structure and critical quality attributes.
- Process development: Establish and optimize synthesis or biological production.
- Analytical method development: Develop methods for identity, purity, impurities and stability.
- Purification optimization: Improve recovery while controlling impurities.
- Stability evaluation: Investigate degradation pathways and storage conditions.
- Scale-up and transfer: Demonstrate suitability at the intended scale.
- Quality and regulatory support: Prepare documentation showing the process and product meet applicable requirements.
Not every project needs every step, and the sequence may differ by modality. A CDMO with strong analytical capability can add real value in early development and technology transfer, even when another qualified organization performs the manufacturing.
What Regulatory and Quality Standards Apply?
Both modalities must meet GMP expectations and demonstrate control through validated methods, but the guidance that applies differs. Peptides are generally assessed under ICH impurity and specification guidelines and, for generics, FDA’s synthetic peptide expectations. Biologics fall under the ICH Q5 series, ICH Q6B and, where relevant, biosimilar frameworks. Across both:
- Data integrity: Records should follow ALCOA+ principles, with audit trails for analytical systems.
- Method validation: Methods should be fit for purpose and validated in line with ICH Q2(R2) as the program advances.
- Impurity control: Product- and process-related impurities need defined, data-justified limits.
- Change control and comparability: Process changes should be supported by comparability evidence.
Always confirm current requirements with the relevant regulator, since guidance evolves and expectations vary by product.
How Does ResolveMass Laboratories Inc. Support Peptide and Biologics Development?
ResolveMass supports pharmaceutical development through specialized analytical testing and characterization that address molecular identity, impurity and product quality questions. For companies evaluating Peptide and Biologics CDMO Services, it helps to decide first whether the need is manufacturing, analytical characterization or a coordinated combination of both.
Relevant analytical support may include:
- Peptide characterization: Mass spectrometry-based identity confirmation and investigation of peptide-related impurities
- LC-MS and LC-HRMS analysis: Characterization of molecular species and investigation of unexpected impurities or degradation products
- Impurity profiling: Assessment of process-related, product-related and degradation-related impurities
- Stability and degradation studies: Investigation of molecular integrity under stress or storage conditions
- Analytical method development: Methods matched to the molecule, objective and intended application
- Polymer and formulation-related characterization: Analytical work for delivery systems and complex formulations, including PLGA-based systems, depending on project needs
For biologics, the plan may require specialized methods for intact mass, peptide mapping, glycosylation, aggregation or biological activity. Specific capabilities and scope should be confirmed directly with the laboratory.
Important distinction: Analytical characterization services do not by themselves establish that a provider manufactures peptides or biologics in-house. If you need drug substance or finished drug product manufacturing, verify manufacturing capacity, facility qualifications, cGMP status and responsibility for each project stage.
Conclusion:
A CDMO can support both peptide and biologic manufacturing when it has the necessary modality-specific infrastructure, expertise, quality systems and controls. Because chemical peptide synthesis and biologics production differ so much, each provider’s capabilities need careful evaluation.
Frequently Asked Questions:
Peptide and Biologics CDMO Services support the development, manufacturing, and quality assessment of peptide therapeutics and biological drugs. Depending on the provider, these services may include process development, purification, analytical characterization, impurity profiling, stability testing, and commercial manufacturing.
Peptide manufacturing commonly uses chemical synthesis methods such as solid-phase peptide synthesis (SPPS), followed by purification and characterization. Biologics manufacturing typically involves biological expression systems, such as mammalian cell culture or microbial fermentation, followed by downstream purification and extensive structural and functional testing.
Evaluate the CDMO’s experience with your molecule, manufacturing infrastructure, analytical capabilities, quality management systems, scalability, and regulatory support. Ask for evidence of relevant project experience and clarify which services are performed in-house. The provider should be able to demonstrate that its capabilities match your project’s technical requirements.
Commercial manufacturing and many regulated clinical manufacturing activities require compliance with applicable current Good Manufacturing Practice (cGMP) requirements. Early research and analytical development may operate under different requirements depending on the intended use. Companies should verify the facility’s regulatory status and quality controls for their specific project.
Reference
- Noriega-Fernandes B, Ibrahim M, Cruz R, Kuehl PJ, Shepard KB. Navigating the development of dry powder for inhalation: a CDMO perspective. Pharmaceuticals. 2025 Mar 19;18(3):434.https://www.mdpi.com/1424-8247/18/3/434
- Barry CS. The Role of Contract Manufacturing in Antibody–Drug Conjugate (ADC) Drug Substance Development–Strategies for Successful Engagement. AAPS PharmSciTech. 2026 Jul 9;27(5):255.https://link.springer.com/article/10.1208/s12249-026-03466-8
- Sengoku S, Kawata Y. Sustainability considerations and research in the biopharmaceutical industry. InSustainability in the Manufacturing of Pharmaceuticals 2025 Jan 1 (pp. 259-279). Academic Press.https://www.sciencedirect.com/science/chapter/edited-volume/pii/B9780443289217000026
- Mayer K. CDMOs Forge Links to Next-Gen Antibody Conjugates: To offer even more comprehensive ADC capabilities, CDMOs are pioneering site-specific linker technologies, broadening their payload options, and preparing for indications beyond oncology. Genetic Engineering & Biotechnology News. 2020 Dec 1;40(12):24-8.https://journals.sagepub.com/doi/abs/10.1089/gen.40.12.08
About the Author
